<bill session="116" type="h" number="5497" updated="2022-10-28T01:46:13Z">
  <state datetime="2019-12-19">REFERRED</state>
  <status>
    <introduced datetime="2019-12-19"/>
  </status>
  <introduced datetime="2019-12-19"/>
  <titles>
    <title type="display">Conditional Approval Act</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited conditional approval pathway, subject to specific obligations, for certain drugs, and for other purposes.</title>
    <title type="short" as="introduced">Conditional Approval Act</title>
  </titles>
  <sponsor bioguide_id="W000821"/>
  <cosponsors>
    <cosponsor bioguide_id="B001309" joined="2019-12-19"/>
    <cosponsor bioguide_id="G000579" joined="2019-12-19"/>
  </cosponsors>
  <actions>
    <action datetime="2019-12-19">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-12-19" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-12-20">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="s" number="3133" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Civil actions and liability"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Health care coverage and access"/>
    <term name="Health information and medical records"/>
    <term name="Marketing and advertising"/>
    <term name="Medical research"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-03T15:21:03Z" status="Introduced in House">Conditional Approval Act

This bill authorizes the Food and Drug Administration to conditionally approve certain new drugs intended for diseases that are seriously debilitating, life threatening, or chronic, and for which meaningful treatments do not exist. The bill also limits liability related to these conditionally approved drugs.</summary>
</bill>
